Drug discovery data just keeps getting bigger…and bigger….and more complex. This blog offers some solutions to the data deluge.
Drug discovery is hard (nine out of ten drug candidates fail), time-consuming (typically 10 - 15 years), and expensive (Tufts’ 2016 estimate $2.87Bn).
The experts at PerkinElmer have worked with thousands of customers to help them select an electronic lab notebook solution. Here are four time-tested steps to cut your search time and quickly identify the best ELN for your organization.
An “in-the-trenches” perspective on ELN is provided by guest author, Rick Betori, a National Institutes of Health Chemistry-Biology Interface Predoctoral Fellow and a Northwestern Department of Chemistry Departmental Fellow.
A review of PerkinElmer's newest new demonstration laboratory at NutriControl, part of a Dutch cooperative enterprise with business interests throughout Europe, Russia, China, and South America.
How Perten Instruments and PerkinElmer are helping the agricultural and food industries feed the world and keep us all safe.
PerkinElmer's role in the historic Cassini spacecraft mission to Saturn.
New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the AlphaLISA human PD-L1 assay.
The Australian Institute of Marine Science (AIMS) is helping to sustain and restore damage to ecosystems due to a changing climate and microplastics contamination in the Great Barrier Reef.
North York General Hospital researchers have developed an Enhanced First Trimester Screen that is faster, less costly, but just as accurate as the standard Integrated Prenatal Screening protocol in detecting the risk for Down syndrome and Trisomy 18. The new test was developed with the help of PerkinElmer and is now in use in Ontario, Canada.